Is It Time To Review The Vaccination Strategy To Protect Adults Against Invasive Pneumococcal Disease?
journal contributionposted on 2022-03-15, 16:44 authored by Mary Corcoran, Jolita Mereckiene, Stephen Murchan, Martha McElligott, D O’Flanagan, Suzanne Cotter, Robert CunneyRobert Cunney, Hilary HumphreysHilary Humphreys
Pneumococcal conjugate vaccines (PCVs) have reduced the predominant serotypes causing invasive pneumococcal disease (IPD). We assessed the impact of the paediatric 7- and 13-valent pneumococcal conjugate vaccines (PCV7 and PCV13) among older adults. We compared serotype-specific incidence rates from 2007/08 to 2016/17, expressed as incidence rate ratios (IRR). Introducing PCV7 and PCV13 into the childhood immunisation programme resulted in a decline in these serotypes in adults ≥65 years of age, with PCV7 serotypes decreasing by 85% (IRR=0.11, 95%CI: 0.05-0.22, p
Royal College of Surgeons Ireland, Temple Street Children's University Hospital, Health Protection Surveillance Centre and previously through Pfizer Ireland (unrestricted grant). We are alsopartially supported by the ECDC (SpIDnet project) and the European Commission (Horizon 2020).
CommentsThe original article is available at imj.ie
Published CitationCorcoran M, Mereckiene J, Murchan S, McElligott M, O’Flanagan D, Cotter S, Cunney R, Humphreys H. Is It Time To Review The Vaccination Strategy To Protect Adults Against Invasive Pneumococcal Disease? Irish Medical Journal. 2019;112(3):894.
- Beaumont Hospital
- Clinical Microbiology